Genentech Wins Patent Case Brought By Chiron
This article was originally published in The Pink Sheet Daily
Executive Summary
A Chiron patent claiming monoclonal antibodies that bind selectively to the HER-2 antigen is invalid, a federal appeals court ruled March 30